26th Apr 2011 15:47
FOR IMMEDIATE RELEASE
26 April 2011
SkyePharma PLC - Annual Information Update
In accordance with the requirements of Prospectus Rule 5.2, the following information and documents were published, or made available to the public, over the 12 months from 27 April 2010 to 26 April 2011 (inclusive) in compliance with laws and rules dealing with the regulation of securities, issuers of securities and securities markets.
This annual information update is required by, and is being made pursuant to Prospectus Article 10 of the Prospectus Directive as implemented in the UK by Prospectus Rule 5.2.3G made by the Financial Services Authority and not for any other purpose and by filing this annual information update neither SkyePharma PLC ('the Company'), nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information contained herein or referred to below. The information contained below or referred to below is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Furthermore, such information may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction. Neither this annual information update, nor the information referred to below constitutes, by virtue of this communication, an offer of any securities addressed to any person and should not be relied on in such respect by any person.
1. Announcements via RNS
The following UK regulatory announcements have been made via RNS a Regulatory Information Service and can be obtained from the London Stock Exchange website at www.londonstockexchange.com or the Company's website at www.skyepharma.com
Date | Announcement |
27/04/10 | Annual Information Update |
05/05/10 | Board Change |
11/05/10 | Holding(s) in Company |
12/05/10 | Interim Management Statement |
12/05/10 | AGM Statement |
15/06/10 | Share Purchase Plan |
23/06/10 | Director Declaration |
24/06/10 | Research Update |
16/07/10 | Director/PDMR Shareholding |
19/07/10 | Holding(s) in Company |
06/08/10 | Director/PDMR Shareholding |
17/08/10 | Appointment of CEO |
19/08/10 | Half Yearly Report |
19/08/10 | Director/PDMR Shareholding |
20/08/10 | Regains US marketing rights to Flutiform™ |
03/09/10 | Director/PDMR Shareholding |
10/09/10 | Director/PDMR Shareholding |
12/10/10 | Director/PDMR Shareholding |
21/10/10 | Interim Management Statement |
08/11/10 | Director/PDMR Shareholding |
22/11/10 | Research Update |
03/12/10 | Trading Update |
09/12/10 | Director/PDMR Shareholding |
10/01/11 | Change of Adviser |
11/01/11 | Director/PDMR Shareholding |
04/02/11 | Director/PDMR Shareholding |
07/03/11 | Discontinuation of PULMICORT pMDI production |
10/03/11 | Director/PDMR Shareholding |
23/03/11 | Final Results |
07/04/11 | Annual Report and Accounts |
11/04/11 | Director/PDMR Shareholding |
2. Documents filed at Companies House
All of the documents listed below were filed with the Registrar of Companies in England and Wales on the dates indicated. Copies of the documents filed with the Registrar of Companies can be obtained from Companies House (www.companieshouse.gov.uk)
Date of Filing | Brief Description of document(s) filed (date entered on public file in brackets if applicable) | |
27/05/10 | RES01 | Alteration to Memorandum and Articles of Association (05/04/11) |
27/05/10 | MEM/ARTS | Articles of Association (06/04/11) |
27/05/10 | AA | Annual Report and Accounts |
27/05/10 | CO04 | Statement of Company's Objects |
27/05/10 | RES09 | Authority to Purchase Shares (05/04/11) |
27/05/10 | RES10 | Authorised Allotment of Shares (05/04/11) |
27/05/10 | RES11 | Disapplication of Pre-Emption Rights (05/04/11) |
27/05/11 | RES13 | Directors' Authority (06/04/11) |
31/08/10 | AP01 | Director Appointed |
01/10/10 | TM01 | Termination of Director's Appointment |
10/01/11 | AD01 | Change of Registered Office |
31/01/11 | AR01 | Annual Return (01/02/11) |
3. Documents published or sent to Shareholders or filed with the National Storage Mechanism and available from www.hemscott.com/nsm.do:
Date | Document |
12/05/10 | Resolutions passed at AGM |
19/08/10 | Half Yearly Report 2010 |
07/04/11 | Annual Report 2010 |
07/04/11 | Notice of Annual General Meeting 2011 |
07/04/11 | Form of Proxy |
Copies of the above documents can be obtained from the Company Secretary at:
SkyePharma PLC
46-48 Grosvenor Gardens
London
SW1W 0EB
All of the above information was up-to-date at the time of publication but it is acknowledged that such disclosures may, at any time, be out of date due to changing circumstances.
For further information please contact:
SkyePharma PLC
John Murphy (Company Secretary) +44 207 881 0524
Singer Capital Markets Limited
Shaun Dobson / Claes Spång +44 203 205 7500
Financial Dynamics
Jonathan Birt /Sue Quigley +44 207 831 3113
About SkyePharma PLC
Using its proprietary drug delivery technologies, SkyePharma develops new formulations of known molecules to provide a clinical advantage. The Group has twelve approved products in the areas of oral, inhalation and topical delivery. The Group's products are marketed throughout the world by leading pharmaceutical companies. For more information, visit www.skyepharma.com.
Related Shares:
SKP.L